×
About 7,100 results

ALLMedicine™ Mantle Cell Lymphoma Center

Research & Reviews  1,845 results

Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with lep...
https://doi.org/10.1136/bcr-2022-249631
BMJ Case Reports; Yohannan B, Sridhar A et. al.

Jun 23rd, 2022 - Mantle cell lymphoma (MCL) is an incurable B cell non-Hodgkin's lymphoma with a variable clinical course. Central nervous system (CNS) involvement is a rare and dreaded complication in MCL. We report a case of leptomeningeal relapse of MCL that wa...

Tipping the balance: toward rational combination therapies to overcome venetoclax resis...
https://doi.org/10.1038/s41375-022-01627-9 10.1172/JCI61272 10.1182/blood.2021013326 10.1158/1078-0432.CCR-20-4842 10.3324/haematol.2018.198812 10.1002/ajh.25796 10.1038/s41568-021-00407-4 10.3390/cells9030717 10.1038/s41419-020-03144-y 10.3390/cancers12040938 10.1182/blood.2019004326 10.1016/j.ccell.2019.08.005 10.1182/blood.2019003722 10.1182/bloodadvances.2021006211 10.1002/ajh.26411 10.1038/s41467-018-03170-7 10.1038/s41591-018-0243-z 10.1016/j.blre.2020.100672 10.1016/j.clml.2019.09.081 10.1182/blood.2020008017 10.1016/j.semcancer.2011.09.007 10.1111/joim.12633 10.1038/onc.2016.155 10.1038/cdd.2017.169 10.3389/fonc.2018.00645 10.1016/j.tcb.2013.07.006 10.1038/leu.2011.46 10.1038/onc.2016.515 10.1111/febs.14122 10.1038/s41580-020-0255-7 10.1038/nrclinonc.2018.8 10.1080/10428194.2017.1357177 10.3389/fonc.2018.00458 10.1182/bloodadvances.2016004176 10.3324/haematol.2017.182048 10.1182/blood-2008-10-185827 10.1182/bloodadvances.2020003871 10.3324/haematol.2021.279800 10.3324/haematol.2022.280721 10.1016/j.bbamcr.2015.07.009 10.1038/s41420-022-00884-y 10.1007/s10238-013-0268-z 10.1038/s41467-021-26613-0 10.1182/blood-2015-11-681460 10.1002/hon.2251 10.1371/journal.pone.0153823 10.1182/blood-2013-02-482125 10.1182/blood-2014-12-619163 10.1038/leu.2017.32 10.1111/bjh.13149 10.1182/blood-2015-10-675009 10.1007/s00262-021-03043-x 10.1056/NEJMoa1715519 10.1182/blood.2020008727 10.1186/s13045-021-01188-x 10.1182/blood.2021014488 10.1182/blood.2020008608 10.3324/haematol.2011.052779 10.1080/10428194.2019.1643463 10.1038/s41375-020-0934-6 10.1182/bloodadvances.2019000844 10.1158/1078-0432.CCR-17-3004 10.1182/blood-2021-150942 10.1182/blood-2019-123404 10.1182/blood-2010-01-262808 10.1038/s41416-020-01205-9 10.1158/1078-0432.CCR-12-2185 10.1111/bjh.15282 10.1182/blood-2011-03-340109 10.1002/1878-0261.13153 10.1182/blood-2015-04-640920 10.1038/s41418-020-00692-w 10.3390/ijms21145164 10.3390/cancers12102725 10.1186/s13045-020-00962-7 10.3390/cancers14020293 10.1016/j.ccell.2019.04.005 10.1038/s41375-019-0652-0 10.1038/s41375-022-01553-w 10.1158/1078-0432.CCR-10-3412 10.1038/leu.2017.207 10.1182/blood-2015-04-639542 10.1182/blood-2021-153733 10.3324/haematol.2017.172882 10.1182/bloodadvances.2021004619 10.3324/haematol.2018.204701 10.1126/scitranslmed.aaq1240 10.1182/blood.2021013990 10.1056/NEJMoa1815281 10.1200/JCO.20.00948 10.1182/blood-2021-151831 10.1182/blood-2021-153390 10.1038/leu.2011.2 10.1182/blood-2015-12-687814 10.1158/1078-0432.CCR-17-1144
Leukemia Thus YJ, Eldering E et. al.

Jun 21st, 2022 - Mantle cell lymphoma (MCL), an aggressive, but incurable B-cell lymphoma, is genetically characterized by the t(11;14) translocation, resulting in the overexpression of Cyclin D1. In addition, deregulation of the B-cell lymphoma-2 (BCL-2) family p...

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04599634

Jun 16th, 2022 - Background: Indolent B-cell malignancies are associated with frequent disease relapse Standard frontline therapy includes a monoclonal anti-CD20 antibody with or without chemotherapy; novel targeted therapies have changed the treatment landscape a...

Vaccine Responses in Patients With B Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT05170399

Jun 16th, 2022 - Description: This study aims to determine vaccine titers in B-cell malignancies; specifically, in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or other non-Hodgkin lymphomas (NHL) [follicular lymphoma (FL), mantle cell lymp...

Targeting the immune microenvironment in mantle cell lymphoma: implications for current...
https://doi.org/10.1080/10428194.2022.2086244
Leukemia & Lymphoma; Qualls D, Kumar A et. al.

Jun 16th, 2022 - Mantle cell lymphoma (MCL) is a morphologically and phenotypically heterogeneous subtype of non-Hodgkin lymphoma, and has historically been associated with poor outcomes. However, recent advances in our understanding of this disease have yielded n...

see more →

Guidelines  3 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines fo...
https://doi.org/10.1093/annonc/mdx223
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Campo E et. al.

Sep 9th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,

Non-Hodgkin's lymphomas, version 4.2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839265
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Sep 6th, 2014 - Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL case...

see more →

Drugs  25 results see all →

Clinicaltrials.gov  129 results

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04002947

Jun 16th, 2022 - Background: Gene-expression profiling (GEP) has identified two dominant molecular subtypes, activated B cell like (ABC) and germinal center B cell like (GCB), that arise by distinct mechanisms, have distinct prognoses, and respond differently to t...

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04599634

Jun 16th, 2022 - Background: Indolent B-cell malignancies are associated with frequent disease relapse Standard frontline therapy includes a monoclonal anti-CD20 antibody with or without chemotherapy; novel targeted therapies have changed the treatment landscape a...

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

Jun 16th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...

Vaccine Responses in Patients With B Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT05170399

Jun 16th, 2022 - Description: This study aims to determine vaccine titers in B-cell malignancies; specifically, in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or other non-Hodgkin lymphomas (NHL) [follicular lymphoma (FL), mantle cell lymp...

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03647124

Jun 15th, 2022 - This is a European multinational, retrospective, non-interventional study of participants with relapsed or refractory mantle cell lymphoma (R/R MCL). Potential sites will be identified where R/R MCL participants have been treated with lenalidomide...

see more →

News  838 results

'Profound' Results With Ibrutinib Add-On in Mantle Cell Lymphoma 
https://www.medscape.com/viewarticle/975055

Jun 4th, 2022 - Dr Michael Wang The largest trial to date in mantle cell lymphoma shows that adding the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) to standard of care treatment improves progression-free survival (PFS) by 50%. The phase 3 SHINE...

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl

May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma
https://www.onclive.com/view/car-nk-cell-therapies-show-preliminary-safety-and-efficacy-in-aml-non-hodgkin-lymphoma

Apr 25th, 2022 - The novel allogeneic CAR-engineered natural killer (NK) cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia (AML) and non-Hodgkin ...

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL
https://www.onclive.com/view/dr-dietrich-on-optimizing-treatment-options-for-patients-in-mcl

Apr 12th, 2022 - Martin Dietrich, MD, PhD, physician, Florida Cancer Specialists and Research Institute, assistant professor of internal medicine, University of Central Florida, discusses optimizing treatment options for patients with mantle cell lymphoma (MCL). ...

Dr. Dietrich on the Current Treatment Landscape of MCL
https://www.onclive.com/view/dr-dietrich-on-the-current-treatment-landscape-of-mcl

Apr 1st, 2022 - Martin Dietrich, MD, PhD, physician, Florida Cancer Specialists and Research Institute, assistant professor of internal medicine, University of Central Florida, discusses the current treatment landscape of mantle cell lymphoma (MCL). Treatment op...

see more →